After Erling Haaland, Guirassy is the second player in the history of the club to top the Champions League goalscoring charts ...

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a ...

Connected drug delivery devices integrate digital connectivity — often via Bluetooth — with traditional drug administration ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- What Does The C5 Complement Inhibitors Market Landscape Look Like? The market for C5 complement inhibitors, critical ...

In the latest instalment of a long-running dispute, the Court of Appeal has recently upheld the High Court judge's view on ...

In 2025, the global proteose peptone market is anticipated to be worth USD 151.4 million, with projections indicating a rise ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Merck KGaA said pimicotinib, an orally administered inhibitor for tenosynovial giant cell tumor, delivered positive results in a late-phase study. The German life-sciences and electronics company said ...

Thyssenkrupp nucera AG & Co. KGaA (Dortmund, Germany) and Fraunhofer IKTS opened the first SOEC pilot production plant for electrolysis stacks on May ...

During the meeting, Senator Dr. Rasha Kelej officially appointed H.E. Senator Oluremi Tinubu as the Ambassador of “Merck ...